John H Newman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8075514/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of Immunopathology and Small Airway Remodeling in Constrictive Bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	11
2	Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. Genetics in Medicine, 2021, 23, 259-271.	1.1	18
3	Familial Autonomic Ganglionopathy Caused by Rare <i>CHRNA3</i> Genetic Variants. Neurology, 2021, 97, e145-e155.	1.5	12
4	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
5	One is the loneliest number: genotypic matchmaking using the electronic health record. Genetics in Medicine, 2021, 23, 1830-1832.	1.1	6
6	Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. American Journal of Human Genetics, 2021, 108, 1946-1963.	2.6	25
7	<i>BMPR2</i> dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L429-L441.	1.3	17
8	Phenotypic Profiling in Subjects Heterozygous for 1 of 2 Rare Variants in the Hypophosphatasia Gene (ALPL). Journal of the Endocrine Society, 2020, 4, bvaa084.	0.1	6
9	Vascular homeostasis at highâ€altitude: role of genetic variants and transcription factors. Pulmonary Circulation, 2020, 10, 1-11.	0.8	6
10	Limitations of exome sequencing in detecting rare and undiagnosed diseases. American Journal of Medical Genetics, Part A, 2020, 182, 1400-1406.	0.7	51
11	Pulmonary Hypertension by the Method of Paul Wood. Chest, 2020, 158, 1164-1171.	0.4	11
12	Six-minute walk distance in healthy young adults. Respiratory Medicine, 2020, 165, 105933.	1.3	43
13	Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy. Clinical Imaging, 2019, 58, 108-113.	0.8	6
14	IgG4â€related disease: Association with a rare gene variant expressed in cytotoxic T cells. Molecular Genetics & Genomic Medicine, 2019, 7, e686.	0.6	8
15	Whole genome sequencing reveals novel <i>IGHMBP2</i> variant leading to unique cryptic spliceâ€site and Charcotâ€Marieâ€Tooth phenotype with early onset symptoms. Molecular Genetics & Genomic Medicine, 2019, 7, e00676.	0.6	18
16	Phenotypic heterogeneity of ZMPSTE24 deficiency. American Journal of Medical Genetics, Part A, 2018, 176, 1175-1179.	0.7	11
17	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183
18	Rare Variants in the Gene ALPL That Cause Hypophosphatasia Are Strongly Associated With Ovarian and Uterine Disorders. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2234-2243.	1.8	7

John H Newman

#	Article	IF	CITATIONS
19	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 896-902.	1.5	6
20	Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 624-634.	0.8	20
21	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2525-2536.	1.2	160
22	Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 719-728.	2.5	75
23	Hemodynamic Evidence of Vascular Remodeling in Combined Post―and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	0.8	38
24	Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1936-1944.	1.6	169
25	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	1.1	185
26	Design and Effectiveness of an Animated Module that Integrates Basic and Clinical Pulmonary Mechanics for Medical Students. Medical Science Educator, 2015, 25, 13-18.	0.7	1
27	Effect of Acute Arteriolar Vasodilation on Capacitance and Resistance in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1080-1085.	0.4	20
28	Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension. Circulation, 2015, 131, 401-409.	1.6	72
29	Use of Pulmonary Arterial Hypertension–Approved Therapy in the Treatment of Non–Group 1ÂPulmonary Hypertension at US Referral Centers. Pulmonary Circulation, 2015, 5, 356-363.	0.8	39
30	Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension. Nature Communications, 2015, 6, 6863.	5.8	69
31	Lungs at high-altitude: genomic insights into hypoxic responses. Journal of Applied Physiology, 2015, 119, 1-15.	1.2	24
32	Variability in Hemodynamic Evaluation of Pulmonary Hypertension at Large Referral Centers. Pulmonary Circulation, 2014, 4, 679-684.	0.8	6
33	High Prevalence of Occult Pulmonary Venous Hypertension Revealed by Fluid Challenge in Pulmonary Hypertension. Circulation: Heart Failure, 2014, 7, 116-122.	1.6	151
34	The First Annual Drug Discovery and Development Symposium for Pulmonary Hypertension. Pulmonary Circulation, 2014, 4, 533-534.	0.8	1
35	Causes of Pulmonary Hypertension in the Elderly. Chest, 2014, 146, 159-166.	0.4	54
36	Right Heart Adaptation to Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2013, 62, D22-D33.	1.2	770

John H Newman

#	Article	IF	CITATIONS
37	Prostanoids But Not Oral Therapies ImproveÂRight Ventricular Function in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2013, 1, 300-307.	1.9	31
38	Clinical Trials in Pulmonary Hypertension: Time for a Consortium. Pulmonary Circulation, 2013, 3, 245-251.	0.8	4
39	Physical Activity Limitation as Measured by Accelerometry in Pulmonary Arterial Hypertension. Chest, 2012, 142, 1391-1398.	0.4	66
40	Chasing Pulmonary Hypertension: 1980–2012. Advances in Pulmonary Hypertension, 2012, 11, 121-123.	0.1	0
41	End Tidal CO 2 Tension. Chest, 2011, 140, 1267-1273.	0.4	19
42	High-Altitude Pulmonary Hypertension in Cattle (Brisket Disease): Candidate Genes and Gene Expression Profiling of Peripheral Blood Mononuclear Cells. Pulmonary Circulation, 2011, 1, 462-469.	0.8	46
43	Association of the Metabolic Syndrome With Pulmonary Venous Hypertension. Chest, 2009, 136, 31-36.	0.4	157
44	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	1.2	605
45	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S32-S42.	1.2	342
46	Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies. Annals of Internal Medicine, 2008, 148, 278.	2.0	83
47	Genetic basis of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S33-S39.	1.2	227
48	Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nature Genetics, 1997, 15, 277-280.	9.4	260